Article Text

Download PDFPDF
Multiple sclerosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: My department has received funding from Genzyme for clinical trials and experimental work on alemtuzumab as a treatment of multiple sclerosis. I have received travel expenses for speaking at meetings about alemtuzumab.

Linked Articles

  • Editor’s choice
    Charles Warlow

Other content recommended for you